Sign inCreate account

Report workspace

Add to folder
NCT04287660UNKNOWNanonymous

A Phase 3, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of Clarithromycin(Biaxin)-Lenalidomide-Low-Dose-Dexamethasone (BiRd) Combined With B-cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Newly Diagnosed Multiple Myeloma

Sponsor

Source record

The First Affiliated Hospital of Soochow University

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

B-cell Maturation Antigen (BCMA) and associated signaling pathways involved in multiple myeloma pathogenesis.

Indication / condition

AI-normalized

Multiple Myeloma

Intervention

Source record

clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells

Source & freshness

Source record

NCT ID

NCT04287660

Original source

ClinicalTrials.gov

Source last updated

Oct 25, 2021

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04287660

Title

A Phase 3, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of Clarithromycin(Biaxin)-Lenalidomide-Low-Dose-Dexamethasone (BiRd) Combined With B-cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Newly Diagnosed Multiple Myeloma

Sponsor

The First Affiliated Hospital of Soochow University

Status

UNKNOWN

Phase

Phase 3

Condition raw

Multiple Myeloma

Condition normalized

Multiple Myeloma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

B-cell Maturation Antigen (BCMA) and associated signaling pathways involved in multiple myeloma pathogenesis.

Target normalized

B-cell Maturation Antigen (BCMA) and associated signaling pathways involved in multiple myeloma pathogenesis.

Interventions

clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells

Public preview

Source record

The BiRd regimen, combining clarithromycin, lenalidomide, and low-dose dexamethasone with BCMA-directed CAR T-cell therapy, targets newly diagnosed multiple myeloma (MM) patients, a market with significant unmet needs. The study's innovative approach may enhance treatment efficacy and safety profiles compared to existing therapies. Given the competitive landscape, including established therapies like daratumumab and newer CAR T-cell therapies, successful outcomes could position this combination as a viable treatment option, potentially impacting market share and revenue streams for the sponsoring institution and collaborators. The trial's multi-center design may facilitate broader patient recruitment and data validation, enhancing its commercial viability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of Clarithromycin(Biaxin)-Lenalidomide-Low-Dose-Dexamethasone (BiRd) Combined With B-cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Newly Diagnosed Multiple Myeloma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT04287660

Status

UNKNOWN

Phase

Phase 3

Sponsor

The First Affiliated Hospital of Soochow University

Executive brief

Investment-Ready Snapshot

The BiRd regimen, combining clarithromycin, lenalidomide, and low-dose dexamethasone with BCMA-directed CAR T-cell therapy, targets newly diagnosed multiple myeloma (MM) patients, a market with significant unmet needs. The study's innovative approach may enhance treatment efficacy and safety profiles compared to existing therapies. Given the competitive landscape, including established therapies like daratumumab and newer CAR T-cell therapies, successful outcomes could position this combination as a viable treatment option, potentially impacting market share and revenue streams for the sponsoring institution and collaborators. The trial's multi-center design may facilitate broader patient recruitment and data validation, enhancing its commercial viability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 25, 2021
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04287660

Indication

Multiple Myeloma

Modality

small molecule

Target

B-cell Maturation Antigen (BCMA) and associated signaling pathways involved in multiple myeloma pathogenesis.

Intervention

clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.